Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement - Cyclo Therapeutics ( NASDAQ:CYTH ) , Rafael Holdings ( NYSE:RFL )
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
| Ticker |
Sentiment |
Impact |
|
CYTH
|
Somewhat Bullish
|
53 %
|
|
RFL
|
Bullish
|
56 %
|
